Health Economics›Marginal zone lymphoma›First-line therapy

First-line therapy

Marginal zone lymphoma · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ibrutinib monotherapy Variant #01	—	R 80 133	28d	~44.1 mo	—	~48	~R 3 846 377 PFS proxy · indirect	15
Ibritumomab tiuxetan protocol Variant #18	—	R 27 524	8d	~36.5 mo	—	~139	~R 3 825 804 PFS proxy · indirect	1
Fludarabine monotherapy Variant #01	—	R 11 691	28d	—	—	—	—	1
Chlorambucil monotherapy Variant #12	—	R 2 523	14d	—	69.5 mo	—	—	1

4 of 4 regimens shown